XNAS
CRVO
Market cap61mUSD
Jul 14, Last price
7.11USD
1D
-0.56%
1Q
-27.23%
IPO
-6.32%
Name
Diffusion Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
146.11%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-16m
L+650.08%
CFO
-17m
L+121.89%
Earnings
Aug 07, 2025
Profile
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 7,145 | ||||||||
Cost of revenue | 27,965 | 23,396 | 4,812 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (27,965) | (16,251) | (4,812) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (3,476) | ||||||||
Tax Rate | |||||||||
NOPAT | (27,965) | (16,251) | (1,336) | ||||||
Net income | (16,291) 650.08% | (2,172) -62.57% | (5,803) -75.92% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 46,399 | 810 | |||||||
BB yield | -245.61% | -3.99% | |||||||
| Debt | |||||||||
Debt current | 12,414 | ||||||||
Long-term debt | 36,701 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 2,368 | ||||||||
Net debt | (38,922) | (7,793) | 45,022 | ||||||
| Cash flow | |||||||||
Cash from operating activities | (16,531) | (7,450) | (2,573) | ||||||
CAPEX | (3) | ||||||||
Cash from investing activities | (28,661) | (12,236) | |||||||
Cash from financing activities | 46,399 | 11,149 | |||||||
FCF | (28,286) | (4,515) | (11,381) | ||||||
| Balance | |||||||||
Cash | 38,922 | 7,793 | 4,094 | ||||||
Long term investments | |||||||||
Excess cash | 38,922 | 7,436 | 4,094 | ||||||
Stockholders' equity | (70,667) | (54,435) | (52,269) | ||||||
Invested Capital | 109,869 | 61,812 | 68,099 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 8,073 | 2,661 | 518 | ||||||
Price | 2.34 -69.33% | 7.63 | |||||||
Market cap | 18,891 -6.97% | 20,307 | |||||||
EV | (20,031) | 12,514 | |||||||
EBITDA | (27,965) | (16,251) | (4,812) | ||||||
EV/EBITDA | 0.72 | ||||||||
Interest | 587 | ||||||||
Interest/NOPBT | |||||||||